SG11202009734VA - Integrin targeting ligands and uses thereof - Google Patents

Integrin targeting ligands and uses thereof

Info

Publication number
SG11202009734VA
SG11202009734VA SG11202009734VA SG11202009734VA SG11202009734VA SG 11202009734V A SG11202009734V A SG 11202009734VA SG 11202009734V A SG11202009734V A SG 11202009734VA SG 11202009734V A SG11202009734V A SG 11202009734VA SG 11202009734V A SG11202009734V A SG 11202009734VA
Authority
SG
Singapore
Prior art keywords
targeting ligands
integrin targeting
integrin
ligands
targeting
Prior art date
Application number
SG11202009734VA
Inventor
Zhen Li
Jeffrey Carlson
Anthony Nicholas
Xiaokai Li
Dongxu Shu
Matthew Fowler-Watters
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of SG11202009734VA publication Critical patent/SG11202009734VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202009734VA 2018-04-27 2019-04-26 Integrin targeting ligands and uses thereof SG11202009734VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862663763P 2018-04-27 2018-04-27
US201962790372P 2019-01-09 2019-01-09
PCT/US2019/029393 WO2019210200A1 (en) 2018-04-27 2019-04-26 Integrin targeting ligands and uses thereof

Publications (1)

Publication Number Publication Date
SG11202009734VA true SG11202009734VA (en) 2020-11-27

Family

ID=68294255

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009734VA SG11202009734VA (en) 2018-04-27 2019-04-26 Integrin targeting ligands and uses thereof

Country Status (16)

Country Link
US (1) US20210093725A1 (en)
EP (1) EP3784269B1 (en)
JP (1) JP2021522269A (en)
KR (1) KR20210005145A (en)
CN (1) CN112074290A (en)
AU (1) AU2019260738A1 (en)
BR (1) BR112020021949A2 (en)
CA (1) CA3097656A1 (en)
DK (1) DK3784269T3 (en)
FI (1) FI3784269T3 (en)
IL (2) IL309955A (en)
JO (1) JOP20200266A1 (en)
MX (1) MX2020011290A (en)
SG (1) SG11202009734VA (en)
TW (1) TW202014206A (en)
WO (1) WO2019210200A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4367246A2 (en) * 2021-07-07 2024-05-15 Alnylam Pharmaceuticals, Inc. Integrin targeting ligands for ocular delivery of rnai compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN1284944A (en) * 1997-12-17 2001-02-21 麦克公司 Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2009114776A2 (en) * 2008-03-14 2009-09-17 Visen Medical, Inc. Integrin targeting agents and methods of using same
KR20150009952A (en) * 2012-01-27 2015-01-27 에프. 호프만-라 로슈 아게 Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3
SG10201706960TA (en) * 2013-02-28 2017-10-30 Arrowhead Res Corp Organic compositions to treat epas1-related diseases
AU2014306021B2 (en) 2013-08-07 2018-12-13 Arrowhead Pharmaceuticals, Inc. Polyconjugates for delivery of RNAi triggers to tumor cells in vivo
TWI736529B (en) * 2015-02-19 2021-08-21 美商賽氟洛生命科學公司 Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
US11971402B2 (en) * 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
US9572801B2 (en) * 2015-04-30 2017-02-21 Scifluor Life Sciences, Inc. Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
CN108064156B (en) 2015-05-29 2022-02-01 箭头药业股份有限公司 Composition and method for inhibiting expression of Hif2alpha gene

Also Published As

Publication number Publication date
CA3097656A1 (en) 2019-10-31
KR20210005145A (en) 2021-01-13
IL309955A (en) 2024-03-01
CN112074290A (en) 2020-12-11
BR112020021949A2 (en) 2021-01-26
MX2020011290A (en) 2020-11-13
IL278304B2 (en) 2024-06-01
US20210093725A1 (en) 2021-04-01
DK3784269T3 (en) 2024-07-08
IL278304B1 (en) 2024-02-01
WO2019210200A1 (en) 2019-10-31
JP2021522269A (en) 2021-08-30
TW202014206A (en) 2020-04-16
AU2019260738A1 (en) 2020-10-15
EP3784269A1 (en) 2021-03-03
IL278304A (en) 2020-12-31
JOP20200266A1 (en) 2020-10-21
FI3784269T3 (en) 2024-07-03
EP3784269B1 (en) 2024-06-05
EP3784269A4 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
IL290842A (en) Anti-cd73 antibodies and uses thereof
IL268206A (en) Bcma-targeting antibody and use thereof
IL312910A (en) Anti-galectin-9 antibodies and uses thereof
SG11202100931QA (en) Muscle-targeting complexes and uses thereof
IL267856A (en) Compositions comprising a bifunctional protein targeting pd-l1 and tgfb
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL268734A (en) Anti-lag-3 antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and uses thereof
IL269134A (en) Anti-par2 antibodies and uses thereof
IL268101A (en) Photoreactive ligands and uses thereof
IL275577A (en) Antibodies and variants thereof against pd-l1
SG11202002967SA (en) Integrin ligands and uses thereof
IL268687A (en) Antibody targeting il-13ra2 and use thereof
IL272476A (en) Anti-apelin antibodies and uses thereof
IL273157A (en) Axl-specific antibodies and uses thereof
IL271398A (en) Anti-l1-cam antibodies and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
SG11202003585VA (en) Anti-vista antibody and use thereof
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
IL272164A (en) 3-acyl-benzamides and their use as herbicides
SG11202009734VA (en) Integrin targeting ligands and uses thereof
EP3784267A4 (en) Integrin targeting ligands and uses thereof
IL280369A (en) New myokines and uses thereof
IL274202A (en) Anti-glyco-muc1 antibodies and their uses
GB201804409D0 (en) Compostions and uses thereof